Protection against ischemic brain injury by protein therapeutics
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Preventing massive cell death is an important therapeutic strategy for various injuries and disorders. Protein therapeutics have the advantage of delivering proteins in a short period. We have engineered the antiapoptotic bcl-x gene to generate the super antiapoptotic factor, FNK, with a more powerful cytoprotective activity. In this study, we fused the protein transduction domain (PTD) of the HIV/Tat protein to FNK and used the construct in an animal model of ischemic brain injury. When added into culture media of human neuroblastoma cells and rat neocortical neurons, PTD-FNK rapidly transduced into cells and localized to mitochondria within 1 h. It protected the neuroblastomas and neurons against staurosporine-induced apoptosis and glutamate-induced excitotoxicity, respectively. The cytoprotective activity of PTD-FNK was found at concentrations as low as 0.3 pM. Additionally, PTD-FNK affected the cytosolic movement of calcium ions, which may relate to its neuroprotective action. Immunohistochemical analysis revealed that myc-tagged PTD-FNK (PTD-myc-FNK) injected i.p. into mice can have access into brain neurons. When injected i.p. into gerbils, PTD-FNK prevented delayed neuronal death in the hippocampus caused by transient global ischemia. These results suggest that PTD-FNK has a potential for clinical utility as a protein therapeutic strategy to prevent cell death in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Translocation of SAPK/JNK to Mitochondria and Interaction with Bcl-xL in Response to DNA Damage
Kharbanda, S., Saxena, S., Yoshida, K., Pandey, P., Kaneki, M., Wang, Q., Cheng, K., Chen, Y.-N., Campbell, A., Sudha, T., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.322 · Cited by 429
Cited by
Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals
Ohsawa, I., Ishikawa, M., Takahashi, K., Watanabe, M., Nishimaki, K., Yamagata, K., Katsura, K.-I., Katayama, Y., Asoh, S., & Ohta, S. (2007) · Nature Medicine · doi:10.1038/nm1577 · Cited by 2,560
Self-citationMechanisms, challenges and opportunities in stroke
Lo, E. H., Dalkara, T., & Moskowitz, M. A. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1106 · Cited by 1,781
Cell-Penetrating Peptides: From Basic Research to Clinics
Guidotti, G., Brambilla, L., & Rossi, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.01.003 · Cited by 1,147
GUPTA, B., LEVCHENKO, T., & TORCHILIN, V (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.007 · Cited by 632
RECENT APPROACHES TO INTRACELLULAR DELIVERY OF DRUGS AND DNA AND ORGANELLE TARGETING
Torchilin, V. P. (2006) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.8.061505.095735 · Cited by 543
Transduction peptides: from technology to physiology
Joliot, A., & Prochiantz, A. (2004) · Nature Cell Biology · doi:10.1038/ncb0304-189 · Cited by 495
Cell Membrane Lipid Rafts Mediate Caveolar Endocytosis of HIV-1 Tat Fusion Proteins
Fittipaldi, A., Ferrari, A., Zoppé, M., Arcangeli, C., Pellegrini, V., Beltram, F., & Giacca, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303045200 · Cited by 475
Delivery of bioactive molecules into the cell: the Trojan horse approach
Dietz, G. P. H., & Bähr, M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.03.005 · Cited by 469
Characterisation of cell‐penetrating peptide‐mediated peptide delivery
Jones, S. W., Christison, R., Bundell, K., Voyce, C. J., Brockbank, S. M. V., Newham, P., & Lindsay, M. A. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706279 · Cited by 385
Cell-penetrating peptides as delivery vehicles for biology and medicine
Stewart, K. M., Horton, K. L., & Kelley, S. O. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b719950c · Cited by 381
Tumor hypoxia: A target for selective cancer therapy
Kizaka‐Kondoh, S., Inoue, M., Harada, H., & Hiraoka, M. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01395.x · Cited by 352
Cheng, G., Kong, R., Zhang, L., & Zhang, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02025.x · Cited by 343
Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury
Starkov, A. A., Chinopoulos, C., & Fiskum, G. (2004) · Cell Calcium · doi:10.1016/j.ceca.2004.02.012 · Cited by 339
Cell Penetrating Peptides in Drug Delivery
Snyder, E. L., & Dowdy, S. F. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000019289.61978.f5 · Cited by 323
Molecular Mechanisms of Apoptosis in Cerebral Ischemia: Multiple Neuroprotective Opportunities
Nakka, V. P., Gusain, A., Mehta, S. L., & Raghubir, R. (2008) · Molecular Neurobiology · doi:10.1007/s12035-007-8013-9 · Cited by 261
Yamada, Y., & Harashima, H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.016 · Cited by 259
Hiraga, T., Kizaka-Kondoh, S., Hirota, K., Hiraoka, M., & Yoneda, T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2355 · Cited by 242
“Thus, HIV-TAT fusion proteins can be delivered to tissues where blood vessels are shut down, such as in ischemic brain (21).”
Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells
Racanicchi, S., Maccherani, C., Liberatore, C., Billi, M., Gelmetti, V., Panigada, M., Rizzo, G., Nervi, C., & Grignani, F. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600593 · Cited by 36
Metadata
- Authors
- Asoh, S., Ohsawa, I., Mori, T., Katsura, K.-I., Hiraide, T., Katayama, Y., Kimura, M., Ozaki, D., Yamagata, K., & Ohta, S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-12-10
- Volume
- 99
- Issue
- 26
- Pages
- 17107-17112
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1968479682
- Cited by
- 198
- References
- 1
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.